Candidiasis vulvovaginalis by candida tropicalis in chronic hepatitis B patient: A rare case
A RARE CASE
Keywords:
Candida tropicalis, candidiasis vulvovaginalis, chronic hepatitis BAbstract
Introduction: Vulvovaginal candidiasis (VVC) is an infection caused by Candida, 85-90% by Candida albicans, 20% by non-albicans and due to high recurrence. Risk factor of VVC is immunocompromised patients such as diabetes mellitus and chronic hepatitis B. The purpose of this case report is increasing knowledge to provide appropriate management in VVC cases et causa C. tropicalis in chronic hepatitis B patient. Case: A 34-year-old woman came with vaginal discharge 2 weeks ago and had chronic hepatitis B. Physical examination revealed cottage cheese like discharge. 10% KOH examination showed budding yeast cells and pseudohyphae and fungal culture showed C. tropicalis colonies. Patients were given 100.000 IU of intravaginal suppository for 14 days and showed improvement. Discussion: Non-albicans species such as C. tropicalis are rare causes of VVC but have high virulence and often resistant to antifungals and causes morbidity due to its high recurrence rate. Direct microscopic examination using 10% KOH helps establish the diagnosis of VVC. Culture examination was performed on complicated VVC to determine the etiology. Conclusion: Management of VVC must consider comorbid factors, etiology and VVC episodes. Topical therapy is preferred in VVC et causa C.tropicalis with chronic hepatitis B due to its safety and high effectiveness Keywords: Candida tropicalis, candidiasis vulvovaginalis, chronic hepatitis B.References
Dovnik A, Golle A, Novak D, Arko D, Takač I. Treatment of vulvovaginal candidiasis: A review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(1):5-7.
Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol. 2019;25(27):3527-37.
Sheppard C. Treatment of vulvovaginitis. Aust Prescr. 2020;43(6):195-9.
Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: A complex interaction. Expert Rev Anti Infect Ther. 2016;14(8):765-76.
Powell AM, Nyirjesy P. Recurrent vulvovaginitis. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):967-76.
Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans candida species in vulvovaginitis. J Fungi. 2018;4(4):1-17.
Fernández-Ruiz M, Puig-Asensio M, Guinea J, Almirante B, Padilla B, Almela M et al. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population based surveillance. J Infect. 2015;71(3):385-94.
Arastehfar A, Daneshnia F, Hafez A, Khodavaisy S, Najafzadeh MJ, Charsizadeh A et al. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med Mycol. 2020;58(6):766-73.
Arastehfar A, Daneshnia F, Hafez A, Khodavaisy S, Najafzadeh MJ, Charsizadeh A et al. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med Mycol. 2020;58(6):766-73.
Doß S, Potschka H, Doß F, Mitzner S, Sauer M. Hepatotoxicity of antimycotics used for invasive fungal infections: In vitro results. Biomed Res Int. 2017;4(2):1-12.
